For the quarter ending 2025-09-30, PRPH had $236K increase in cash & cash equivalents over the period. -$3,486K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss from continuing operations | -6,839 | -9,150 |
| Realized loss on marketable debt securities | 0 | 0 |
| Depreciation and amortization | 1,038 | 2,831 |
| Amortization of debt discount | 964 | 849 |
| Impairment loss | 1,263 | - |
| Amortization on operating lease right-of-use assets | 17 | 210 |
| Loss on issuance of debt | -480 | - |
| Stock-based compensation expense | 431 | 1,029 |
| Loss from lease termination | 0 | -1,357 |
| Employee retention tax credit income | 380 | 1,549 |
| Inventory reserve | 0 | 0 |
| Loss (gain) from disposal of fixed assets | 0 | -868 |
| Change in fair value of warrant liability | 185 | 40 |
| Change in fair value of derivative liability | -618 | - |
| Debt extinguishment loss | 220 | -718 |
| Accounts receivable | -21 | 28 |
| Inventory | 0 | -313 |
| Prepaid expenses and other current assets | 406 | 803 |
| Deferred tax asset | 0 | 0 |
| Other assets | 0 | 0 |
| Accounts payable and accrued expenses | 117 | 448 |
| Accrued diagnostic services | -49 | 44 |
| Accrued advertising and other allowances | 0 | 0 |
| Deferred revenue | -109 | -410 |
| Deferred tax liability | 0 | 0 |
| Lease liabilities | -122 | -29 |
| Income tax payable | -1,083 | -613 |
| Other liabilities | 588 | -350 |
| Net cash used in operating activities - continuing operations | -3,486 | -4,225 |
| Net cash provided by (used in) operating activities - discontinued operations | 0 | 597 |
| Net cash used in operating activities | -3,486 | -3,628 |
| Proceeds from sales of marketable securities | 0 | 0 |
| Proceeds from sales of fixed assets | 0 | 120 |
| Capital expenditures | 0 | 0 |
| Net cash provided by investing activities - continuing operations | 0 | 120 |
| Net cash provided by (used in) investing activities - discontinued operations | 0 | 800 |
| Net cash provided by investing activities | 0 | 920 |
| Proceeds from issuance of note payable, net | 2,227 | 687 |
| Proceeds from issuance of note payable to related party, net | 0 | 500 |
| Proceeds from issuance of convertible notes payable | 3,000 | - |
| Proceeds from issuance of common shares, net | 0 | 3,558 |
| Repayment of note payable | 1,505 | 2,511 |
| Net cash provided by financing activities - continuing operations | 3,722 | 2,234 |
| Net cash used in financing activities - discontinued operations | 0 | -35 |
| Net cash provided by financing activities | 3,722 | 2,199 |
| Decrease in cash and cash equivalents | 236 | -509 |
| Cash and cash equivalents at beginning of period | 678 | - |
| Cash and cash equivalents at end of period | 405 | - |
ProPhase Labs, Inc. (PRPH)
ProPhase Labs, Inc. (PRPH)